Submission for Amendments to PBS Listings for Multiple Sclerosis Treatments to Include Prescribing by Nurse Practitioners to PBAC meeting November 2024

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) to advocate for the amendment of current Pharmaceutical Benefits Scheme (PBS) listings to allow nurse practitioners to prescribe fingolimod (Gilenya®), ofatumumab (Kesimpta®), and siponimod (Mayzent®) for the treatment of multiple sclerosis (MS).